By Dr. Benjamin Pradere
The upcoming EAU26 in London will be a landmark congress for bladder cancer (BCa). Expect practice-changing data, riveting debates, and cutting-edge surgical insights packed into a few days. For clinicians involved in urothelial carcinoma, this is not a congress to observe from the sidelines. Here is a curated, day-by-day roadmap to make sure you don’t miss what truly matters.
The congress opens strong on Friday morning with a thematic session dedicated to common BCa problems and controversies. The rapid-fire debate format sets the tone: practical, expert-driven, and directly applicable to daily practice. The afternoon is unmissable. The “Late-breaking and high-impact abstracts” session delivers what delegates come for at EAU: emerging data that will shape tomorrow’s standards. Intravesical innovation with erdafitinib drug-releasing systems, optimised fluorescence-guided strategies with mitomycin-C, and randomised evidence on en-bloc resection techniques promise immediate clinical relevance. The session concludes with surgical outcomes from KEYNOTE-905, addressing neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer (MIBC). To close the day, the video session on robotic urinary diversion offers a perfect transition from data to technique, showcasing neobladder, ileal conduit, and female-specific precision approaches.
Saturday morning is dedicated to integrated therapeutic strategies in urothelial cancer, bringing together systemic therapy, surgery, and patient selection. Immediately after, the Game Changer Session highlights disruptive data or concepts that are likely to rapidly influence clinical practice.
Sunday focuses on high-risk disease. The morning session on high-risk NMIBC and UTUC is grounded in real-world decision-making. The afternoon session, “BCG meets immunotherapy,” distils key lessons from POTOMAC, ALBAN, and CRES, translating complex trials into practical messages for urologists.
The congress concludes with a video session spanning upper tract urothelial cancer (UTUC) and bladder tumours, focusing on en-bloc resection, cryobiopsy, and robotic solutions for complex cases.
| Date | Time | Session | Room |
| Friday, 13 March | 10:45–12:15 | Thematic Session “Common problems and controversies in bladder cancer: Rapid-fire debates” | Orange Area, eURO Auditorium 2 |
|
14:00–15:00 |
Abstract session “Late-breaking and high-impact abstracts” |
Orange Area, Room 3 |
|
|
15:45–16:15 |
Video Session 03 “Robotic urinary diversion: Neobladder, ileal conduit, and precision techniques in female cystectomy” |
Blue Area, George 3 |
|
|
Saturday, 14 March |
08:00–10:00 |
Plenary Session “Urothelial cancer: Towards integrated therapeutic strategies” |
Orange Area, eURO Auditorium 2 |
|
10:00–10:30 |
Orange Area, eURO Auditorium 2 |
||
|
Sunday, 15 March |
10:45–12:15 |
Thematic Session “High-risk NMIBC and UTUC: Real-world decisions” |
Orange Area, eURO Auditorium 2 |
|
15:30–17:00 |
Thematic Session “BCG meets immunotherapy in high-risk NMIBC: Key lessons for urologists from POTOMAC, ALBAN, and CREST” |
Orange Area, Room 3 |
|
|
Monday, 16 March |
12:30–14:00 |
Video Session 17 “UTUC to bladder tumours: En-bloc resection, cryobiopsy and robotic solutions for complex cases” |
Blue Area, George 1 |